Trial Profile

An open-label, single-dose, partially-randomized crossover third pivotal bioequivalence study of oxycodone/naltrexone (ELI 201) in healthy volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Dec 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Oxycodone/naltrexone (Primary) ; Oxycodone
Indications Pain
Focus Pharmacokinetics; Registrational

Most Recent Events

03 Dec 2014 Results published in an Elite Pharmaceuticals media release.
03 Dec 2014 Primary endpoint has been met (bioavailability and bioequivalence of oxycodone/naltrexone controlled-release capsules to oxycodone controlled-release tablet), according to an Elite Pharmaceuticals media release.
26 Aug 2014 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com